SG11201811363YA - Anti-zika virus antibodies and methods of use - Google Patents
Anti-zika virus antibodies and methods of useInfo
- Publication number
- SG11201811363YA SG11201811363YA SG11201811363YA SG11201811363YA SG11201811363YA SG 11201811363Y A SG11201811363Y A SG 11201811363YA SG 11201811363Y A SG11201811363Y A SG 11201811363YA SG 11201811363Y A SG11201811363Y A SG 11201811363YA SG 11201811363Y A SG11201811363Y A SG 11201811363YA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- international
- tarrytown
- zikv
- saw mill
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 3
- 208000020329 Zika virus infectious disease Diseases 0.000 title abstract 3
- 241000907316 Zika virus Species 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 101710141454 Nucleoprotein Proteins 0.000 abstract 1
- 241000897276 Termes Species 0.000 abstract 1
- 208000001455 Zika Virus Infection Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000007501 viral attachment Effects 0.000 abstract 1
- 230000007502 viral entry Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111111111111111111111111110101110111111101111111111011110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/017497 Al 25 January 2018 (25.01.2018) WIP0 I PCT (51) International Patent Classification: William; 777 Old Saw Mill River Road, Tarrytown, NY C07K 16/18 (2006.01) A61K 39/00 (2006.01) 10591 (US). MASON, Peter; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). (21) International Application Number: PCT/US2017/042447 (74) Agent: TERMES, Lance, A.; Schwabe Wiiliamson & Wy- (22) International Filing Date: att, PC, 1211 SW 5th Avenue, Suite 1900, Portland, OR 17 July 2017 (17.07.2017) 97204 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (30) Priority Data: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/363,546 18 July 2016 (18.07.2016) US DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, HN, 62/474,753 22 March 2017 (22.03.2017) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicant: REGENERON PHARMACEUTICALS MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, NY 10591 (US). SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: KYRATSOUS, Christos; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). OLSON, Title: ANTI-ZIKA VIRUS ANTIBODIES AND METHODS OF USE = (54) = ADE:. D2: :16 :DilutI - rt = = = = = _ _ = -40- REGN4203 NgG I) .6 REGN4204 t)igCi453, 'lir REGN4206 (;Icji4ki) = = Virus oozy — , = _ 40 = F1GURE1 1-1 IN C:N (57) : The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to ZIKV glyco- 71' N proteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for - inhibiting or neutralizing ZIKV activity, thus providing a means of treating or preventing ZIKV infection in humans. In some embod- --.... © iments, the invention provides for use of one or more antibodies that bind to the ZIKV for preventing viral attachment and/or entry into Ot host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination 1-1 © with one or more other anti-viral agents or vaccines. ei C [Continued on next page] WO 2018/017497 Al IMEDIMOM0101011MERI00 IIMMEHR0EUVOIMIE (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363546P | 2016-07-18 | 2016-07-18 | |
| US201762474753P | 2017-03-22 | 2017-03-22 | |
| PCT/US2017/042447 WO2018017497A1 (en) | 2016-07-18 | 2017-07-17 | Anti-zika virus antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811363YA true SG11201811363YA (en) | 2019-01-30 |
Family
ID=59416830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811363YA SG11201811363YA (en) | 2016-07-18 | 2017-07-17 | Anti-zika virus antibodies and methods of use |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10421804B2 (en) |
| EP (1) | EP3484917A1 (en) |
| JP (1) | JP6993401B2 (en) |
| KR (1) | KR20190030206A (en) |
| CN (1) | CN109641952A (en) |
| AU (1) | AU2017300277A1 (en) |
| BR (1) | BR112019000798A2 (en) |
| CA (1) | CA3030618A1 (en) |
| CL (1) | CL2019000124A1 (en) |
| CO (1) | CO2019000968A2 (en) |
| IL (1) | IL263818A (en) |
| MA (1) | MA45671A (en) |
| MX (1) | MX2019000761A (en) |
| PH (1) | PH12018502673A1 (en) |
| SG (1) | SG11201811363YA (en) |
| TW (1) | TW201815821A (en) |
| UY (1) | UY37336A (en) |
| WO (1) | WO2018017497A1 (en) |
| ZA (1) | ZA201808603B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018010789A1 (en) | 2016-07-13 | 2018-01-18 | Humabs Biomed Sa | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
| TW201815821A (en) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | Anti-zika virus antibodies and methods of use |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| GB2579940B (en) * | 2017-08-03 | 2022-11-30 | Antheia Inc | Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids |
| WO2019042555A1 (en) | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | Multispecific antibodies specifically binding to zika virus epitopes and uses thereof |
| KR20200132938A (en) * | 2018-03-15 | 2020-11-25 | 추가이 세이야쿠 가부시키가이샤 | Anti-dengue virus antibodies with cross-reactivity against Zika virus and methods of use |
| US11254953B2 (en) | 2018-04-18 | 2022-02-22 | Utah State University | Compositions and methods for zika virus characterization and vaccine development |
| US11884718B2 (en) | 2018-04-24 | 2024-01-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination |
| MA53495A (en) | 2018-08-31 | 2021-12-08 | Regeneron Pharma | DOSING STRATEGY TO MITIGATE CYTOKINE RELEASE SYNDROME FOR CD3/C20 BISPECIFIC ANTIBODIES |
| WO2020061159A1 (en) * | 2018-09-20 | 2020-03-26 | Vanderbilt University | Human antibodies to zika virus |
| EP3883961A1 (en) | 2018-11-20 | 2021-09-29 | Takeda Vaccines, Inc. | Novel anti-zika virus antibodies and uses thereof |
| JP7524214B2 (en) * | 2019-04-03 | 2024-07-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Methods and compositions for inserting antibody coding sequences into safe harbor loci |
| CN111138534B (en) * | 2019-12-31 | 2021-09-28 | 武汉班科生物技术股份有限公司 | Mouse source monoclonal antibody of Zika virus envelope protein |
| CN111100201B (en) * | 2019-12-31 | 2021-09-28 | 武汉班科生物技术股份有限公司 | Murine monoclonal antibody against envelope protein of Zika virus |
| JP2023527169A (en) | 2020-05-20 | 2023-06-27 | タケダ ワクチン，インコーポレイテッド | Methods for Determining Antigen Potency |
| WO2021236225A1 (en) | 2020-05-20 | 2021-11-25 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| EP4153222A1 (en) | 2020-05-20 | 2023-03-29 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| WO2022001803A1 (en) * | 2020-06-28 | 2022-01-06 | 神州细胞工程有限公司 | Method for reducing viral ade effect |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| EP2041177B1 (en) | 2006-06-02 | 2011-12-14 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| TW200838550A (en) * | 2007-02-09 | 2008-10-01 | Novartis Ag | Organic compounds |
| KR20120027055A (en) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | Readily isolated bispecific antibodies with native immunoglobulin format |
| PE20150650A1 (en) | 2012-09-12 | 2015-05-26 | Genzyme Corp | POLYPEPTIDES CONTAINING HR WITH ALTERED GLYCOSILATION AND REDUCED EFFECTIVE FUNCTION |
| TWI682941B (en) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | Antibodies comprising chimeric constant domains |
| JO3701B1 (en) * | 2014-05-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to middle east respiratory syndrome – coronavirus spike protein |
| TW201815821A (en) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | Anti-zika virus antibodies and methods of use |
-
2017
- 2017-07-14 TW TW106123586A patent/TW201815821A/en unknown
- 2017-07-17 EP EP17745595.3A patent/EP3484917A1/en active Pending
- 2017-07-17 MA MA045671A patent/MA45671A/en unknown
- 2017-07-17 JP JP2019502258A patent/JP6993401B2/en active Active
- 2017-07-17 CA CA3030618A patent/CA3030618A1/en not_active Abandoned
- 2017-07-17 US US15/651,387 patent/US10421804B2/en active Active
- 2017-07-17 BR BR112019000798A patent/BR112019000798A2/en not_active IP Right Cessation
- 2017-07-17 CN CN201780041806.7A patent/CN109641952A/en active Pending
- 2017-07-17 MX MX2019000761A patent/MX2019000761A/en unknown
- 2017-07-17 WO PCT/US2017/042447 patent/WO2018017497A1/en active Application Filing
- 2017-07-17 KR KR1020197000620A patent/KR20190030206A/en unknown
- 2017-07-17 AU AU2017300277A patent/AU2017300277A1/en not_active Abandoned
- 2017-07-17 SG SG11201811363YA patent/SG11201811363YA/en unknown
- 2017-07-19 UY UY0001037336A patent/UY37336A/en not_active Application Discontinuation
-
2018
- 2018-12-18 PH PH12018502673A patent/PH12018502673A1/en unknown
- 2018-12-19 IL IL263818A patent/IL263818A/en unknown
- 2018-12-20 ZA ZA2018/08603A patent/ZA201808603B/en unknown
-
2019
- 2019-01-16 CL CL2019000124A patent/CL2019000124A1/en unknown
- 2019-01-31 CO CONC2019/0000968A patent/CO2019000968A2/en unknown
- 2019-08-09 US US16/536,531 patent/US11117955B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190030206A (en) | 2019-03-21 |
| PH12018502673A1 (en) | 2019-11-11 |
| AU2017300277A1 (en) | 2019-02-07 |
| CA3030618A1 (en) | 2018-01-25 |
| MA45671A (en) | 2021-04-07 |
| MX2019000761A (en) | 2019-07-04 |
| ZA201808603B (en) | 2019-08-28 |
| US10421804B2 (en) | 2019-09-24 |
| CO2019000968A2 (en) | 2019-04-30 |
| US20200062831A1 (en) | 2020-02-27 |
| JP2019528050A (en) | 2019-10-10 |
| CN109641952A (en) | 2019-04-16 |
| TW201815821A (en) | 2018-05-01 |
| IL263818A (en) | 2019-01-31 |
| WO2018017497A1 (en) | 2018-01-25 |
| US20180016324A1 (en) | 2018-01-18 |
| BR112019000798A2 (en) | 2019-07-02 |
| JP6993401B2 (en) | 2022-02-04 |
| US11117955B2 (en) | 2021-09-14 |
| UY37336A (en) | 2018-02-28 |
| CL2019000124A1 (en) | 2019-04-05 |
| EP3484917A1 (en) | 2019-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201811448RA (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| SG11201901364VA (en) | Engineered target specific nucleases | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same |